MAINZ BIOMED NV (MYNZ) Stock News
NASDAQ:MYNZ - Nasdaq - NL0015000LC2 - Common Stock - Currency: USD
MYNZ Latest News, Press Relases and Analysis
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update...
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study...
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
Mainz Biomed Expands into Switzerland with labor team w
Mainz Biomed Expands into Switzerland with labor team w...
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering ...
Mainz Biomed Announces Stock Split
Mainz Biomed Announces Stock Split...
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer...
Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet
Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.
Mentions: AUPH
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention...
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
Mainz Biomed Expands into Switzerland with labor team w
Partnership to Launch DNA-Based Colorectal Cancer Screening Test
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month...
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
Updated Screening Guidelines Ensure Broader Access to Colorectal Cancer Screening in Germany
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements...
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population...
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test...
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA Approval
Mentions: DGX
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules...
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
Mainz Biomed Announces Stock Split
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update...
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlert ...
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-Baden